ARWR VS PBH Stock Comparison

Performance

ARWR
10/100

ARWR returned -18.45% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

PBH
10/100

PBH returned 0.56% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

ARWR
63/100

4 analysts offer 12-month price targets for ARWR. Together, they have an average target of 63.86, the most optimistic target put ARWR at 90 within 12-months and the most pessimistic has ARWR at 31.

PBH
75/100

7 analysts offer 12-month price targets for PBH. Together, they have an average target of 71, the most optimistic target put PBH at 71 within 12-months and the most pessimistic has PBH at 71.

Technicals

ARWR
64/100

ARWR receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

PBH
64/100

PBH receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

ARWR
10/100

ARWR has missed earnings 16 times in the last 20 quarters.

PBH
100/100

PBH has missed earnings 0 times in the last 20 quarters.

Profit

ARWR
24/100

Out of the last 20 quarters, ARWR has had 6 profitable quarters and has increased their profits year over year on 2 of them.

PBH
74/100

Out of the last 20 quarters, PBH has had 18 profitable quarters and has increased their profits year over year on 11 of them.

Volatility

ARWR
50/100

ARWR has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.

PBH
48/100

PBH has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Arrowhead Research Corporation Summary

Nasdaq / ARWR

Healthcare

Biotechnology

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Prestige Consumer Healthcare Inc. Summary

New York Stock Exchange / PBH

Healthcare

Medical - Distribution

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Power up your portfolio